| Q30950859 | A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia |
| Q37282443 | Acute decrease in serum magnesium level after ischemic stroke may not predict decrease in neurologic function |
| Q36124879 | Acute stroke hypertension: current and future management. |
| Q50719305 | Admission Low Magnesium Level Is Associated with In-Hospital Mortality in Acute Ischemic Stroke Patients. |
| Q38184638 | Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: translation of knowledge to prevention strategies. |
| Q36629801 | Anesthesia for endovascular neurosurgery |
| Q48648832 | Baseline characteristics of the 4011 patients recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial |
| Q36925093 | Biodegradable Magnesium (Mg) Implantation Does Not Impose Related Metabolic Disorders in Rats with Chronic Renal Failure |
| Q38450837 | Bioethical considerations in translational research: primate stroke |
| Q33863549 | Blood Pressure and Penumbral Sustenance in Stroke from Large Vessel Occlusion. |
| Q94363678 | Blood pressure management in acute stroke |
| Q45104422 | Burden of stroke in Singapore |
| Q36102235 | Cerebral vasospasm and wernicke encephalopathy secondary to adult cyclic vomiting syndrome: the role of magnesium |
| Q36610442 | Cerebral vasospasm pharmacological treatment: an update |
| Q36602392 | Considerations in fluids and electrolytes after traumatic brain injury |
| Q38207521 | Control of blood pressure in hypertensive neurological emergencies |
| Q44972753 | Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. |
| Q37652820 | Controversies and evolving new mechanisms in subarachnoid hemorrhage. |
| Q37244467 | Coronary risk stratification in patients with ischemic stroke or transient ischemic stroke attack. |
| Q28218391 | Current treatments in neurology: stroke |
| Q36344183 | Determining the Feasibility of Ambulance-Based Randomised Controlled Trials in Patients with Ultra-Acute Stroke: Study Protocol for the "Rapid Intervention with GTN in Hypertensive Stroke Trial" (RIGHT, ISRCTN66434824) |
| Q40429078 | Developing drug strategies for the neuroprotective treatment of acute ischemic stroke. |
| Q37318138 | Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study |
| Q47979073 | Effect of magnesium treatment and glucose levels on delayed cerebral ischemia in patients with subarachnoid hemorrhage: a substudy of the Magnesium in Aneurysmal Subarachnoid Haemorrhage trial (MASH-II). |
| Q36578554 | Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy |
| Q51761511 | Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. |
| Q37548345 | Effects of professional rehabilitation training on the recovery of neurological function in young stroke patients |
| Q35129507 | Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial |
| Q38100263 | Emerging neuroprotective drugs for the treatment of acute ischaemic stroke |
| Q36720333 | Experimental treatments for acute ischaemic stroke |
| Q58619261 | Future advances in the treatment of acute ischemic stroke |
| Q34573375 | High dose magnesium infusions are not associated with increased pressor requirements after carotid endarterectomy |
| Q40572032 | Hypomagnesemia in Intracerebral Hemorrhage |
| Q55017757 | Hypomagnesemia in critically ill patients. |
| Q35781131 | IMAGES and FAST-MAG: magnesium for acute ischaemic stroke |
| Q48040210 | Incidence, hemodynamic, and electrical characteristics of spreading depolarization in a swine model are affected by local but not by intravenous application of magnesium |
| Q36385287 | Insights from molecular investigations of traditional Chinese herbal stroke medicines: implications for neuroprotective epilepsy therapy |
| Q36883430 | Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke |
| Q37476969 | Intraoperative magnesium administration does not improve neurocognitive function after cardiac surgery |
| Q37198231 | Intraoperative magnesium infusion during carotid endarterectomy: a double-blind placebo-controlled trial |
| Q41806888 | Intravenous magnesium infusion for the prevention of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage |
| Q48522853 | Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. |
| Q35648103 | Investigational therapies for ischemic stroke: neuroprotection and neurorecovery |
| Q57812836 | Ischaemic Stroke and Transient Ischaemic Attack |
| Q46542163 | Ischemic complications in neurosurgery: use of calcium antagonists |
| Q35931102 | Long-Term Predictors of Social and Leisure Activity 10 Years after Stroke |
| Q88909377 | Low Serum Calcium and Magnesium Levels and Rupture of Intracranial Aneurysms |
| Q58776312 | Magnesium Protects in Episodes of Critical Perfusion after Aneurysmal SAH |
| Q38006668 | Magnesium as an effective adjunct therapy for drug resistant seizures. |
| Q36082058 | Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial |
| Q85181024 | Magnesium in a Polyethylene Glycol Formulation Provides Neuroprotection After Unilateral Cervical Spinal Cord Injury |
| Q36256094 | Magnesium neuroprotection is limited in humans with acute brain injury |
| Q48217559 | Magnesium sulfate does not protect spinal cord against ischemic injury |
| Q48339039 | Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial |
| Q48682377 | Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator-induced thrombolysis |
| Q36839995 | Magnesium sulfate protects oligodendrocyte lineage cells in a rat cell-culture model of hypoxic-ischemic injury |
| Q47640638 | Magnesium sulfate protects the heart against carbon monoxide-induced cardiotoxicity in rats. |
| Q51225097 | Magnesium sulphate and cerebral vasospasm. |
| Q34339164 | Magnesium sulphate only slightly reduces the shivering threshold in humans |
| Q24245572 | Magnesium supplementation for the management of primary hypertension in adults |
| Q36499342 | Magnesium therapy within 48 hours of an aneurysmal subarachnoid hemorrhage: neuro-panacea |
| Q36811695 | Magnesium treatment for neuroprotection in ischemic diseases of the brain. |
| Q38659372 | Magnesium, hemostasis, and outcomes in patients with intracerebral hemorrhage. |
| Q91905443 | Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage |
| Q38036066 | Magnesium: novel applications in cardiovascular disease--a review of the literature |
| Q35159997 | Magnesium: potential roles in neurovascular disease |
| Q36406563 | Management of cerebral vasospasm |
| Q37062028 | Mechanisms underlying cell death in ischemia-like damage to the rat spinal cord in vitro |
| Q37026056 | Methodology of the Field Administration of Stroke Therapy - Magnesium (FAST-MAG) phase 3 trial: Part 1 - rationale and general methods |
| Q30497328 | Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales |
| Q33772181 | Molecular Dissection of Cyclosporin A's Neuroprotective Effect Reveals Potential Therapeutics for Ischemic Brain Injury |
| Q37123385 | Neuroprotectants in stroke therapy |
| Q28199814 | Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke |
| Q24645185 | Neuroprotection for ischemic stroke: past, present and future |
| Q37139898 | Neuroprotection in cerebral ischemia: emphasis on the SAINT trial |
| Q37571562 | Neuroprotection in stroke: past, present, and future |
| Q64260635 | New Insights on the Nutrition Status and Antioxidant Capacity in Multiple Sclerosis Patients |
| Q28192644 | New treatments in acute ischemic stroke |
| Q26849614 | Novel NMDA receptor modulators: an update |
| Q38172294 | Optimising outcome assessment to improve quality and efficiency of stroke trials |
| Q34520092 | Other neuroprotective therapies on trial in acute stroke |
| Q37024492 | Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly |
| Q37514167 | Pharmacotherapy of cerebral ischemia |
| Q34244888 | Plasma magnesium and risk of ischemic stroke among women |
| Q34360614 | Prehospital stroke care: new prospects for treatment and clinical research |
| Q38537388 | Prehospital stroke care: telemedicine, thrombolysis and neuroprotection |
| Q37036998 | Prehospital use of magnesium sulfate as neuroprotection in acute stroke |
| Q36226360 | Prevalence and intensity of pain after stroke: a population based study focusing on patients' perspectives |
| Q37998555 | Progressive lacunar stroke: review of mechanisms, prognostic features, and putative treatments |
| Q28181645 | Randomized clinical stroke trials in 2004 |
| Q31153077 | Recommendations and treatment strategies for the management of acute ischemic stroke. |
| Q37222956 | Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial. |
| Q37409498 | Role of magnesium in the pathogenesis and treatment of migraine. |
| Q36180766 | Role of magnesium sulfate in neuroprotection in acute ischemic stroke |
| Q55446813 | Serum Magnesium Levels and Outcomes in Patients With Acute Spontaneous Intracerebral Hemorrhage. |
| Q38184644 | Small molecule inhibitors in the treatment of cerebral ischemia. |
| Q33928297 | Stroke management |
| Q84777678 | Stroke management |
| Q93501211 | Stroke management |
| Q37098053 | Stroke pathophysiology: management challenges and new treatment advances. |
| Q88410644 | Systematic review of the pharmacological agents that have been tested against spreading depolarizations |
| Q37399439 | Systematic reviews as a tool for planning and interpreting trials |
| Q37767423 | Targeting the brain: neuroprotection and neurorestoration in ischemic stroke. |
| Q36488015 | The 2012 Feinberg Lecture: treatment swift and treatment sure |
| Q64926996 | The Effect of Magnesium Deficiency on Neurological Disorders: A Narrative Review Article. |
| Q38416663 | The Virtual International Stroke Trials Archive (VISTA): results and impact on future stroke trials and management of stroke patients |
| Q43735561 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial |
| Q52572366 | The challenge of blood pressure management in neurologic emergencies. |
| Q42905754 | The relationship between magnesium level and first 72 hours Rankin score and Rankin score in 1 week after an ischemic stroke |
| Q26859190 | The role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesium |
| Q39427028 | The role of magnesium sulfate in the intensive care unit |
| Q46700326 | The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage |
| Q42788333 | The spectrum of management practices in nontraumatic subarachnoid hemorrhage: A survey of high-volume centers in the United States |
| Q28196628 | Treating the acute stroke patient as an emergency: current practices and future opportunities |
| Q40755885 | Unsolved issues in the management of high blood pressure in acute ischemic stroke |
| Q24236792 | Vasoactive drugs for acute stroke |
| Q45228851 | What to do when your brain turns blue? Considerations during aortic arch surgery |
| Q42203810 | When basic research doesn't translate to the bedside--lessons from the magnesium brain trauma study |
| Q48431550 | White matter ischemia: Time to begin integrating experimental and clinical data |
| Q36245471 | Why have neuro-protectants failed?: lessons learned from stroke trials. |
| Q80171015 | [Effect of combination therapy with hypothermia, magnesium and tirilazad in an experimental model of diffuse cerebral ischemia] |
| Q81691991 | [European Stroke Organisation 2008 guidelines for managing acute cerebral infarction or transient ischemic attack : part 2] |